Palbociclib in combination with letrozole as first‐line treatment for advanced breast cancer: A Japanese phase II study

This single‐arm, open‐label, phase II study in 42 Japanese postmenopausal patients with estrogen receptor‐positive/human epidermal growth factor receptor 2‐negative (ER+/HER2−) advanced breast cancer evaluated the efficacy, safety, and pharmacokinetics of first‐line palbociclib (125 mg once daily, 3...

Descripción completa

Detalles Bibliográficos
Autores principales: Masuda, Norikazu, Nishimura, Reiki, Takahashi, Masato, Inoue, Kenichi, Ohno, Shinji, Iwata, Hiroji, Mori, Yuko, Hashigaki, Satoshi, Muramatsu, Yasuaki, Nagasawa, Takashi, Umeyama, Yoshiko, Toi, Masakazu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5834809/
https://www.ncbi.nlm.nih.gov/pubmed/29345736
http://dx.doi.org/10.1111/cas.13507

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5834809/
https://www.ncbi.nlm.nih.gov/pubmed/29345736
http://dx.doi.org/10.1111/cas.13507

Ejemplares similares